Description: Renalytix AI plc focuses on the development of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease. Its solutions are used in kidney disease risk assessment, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was incorporated in 2018 and is based in Cardiff, the United Kingdom. Renalytix AI plc is a subsidiary of EKF Diagnostics Holdings plc.
Home Page: renalytix.com
1460 Broadway
New York,
NY
10036
United States
Phone:
646 397 3970
Officers
| Name | Title |
|---|---|
| Mr. James R. McCullough M.B.A. | CEO & Exec. Director |
| Mr. Fergus Fleming | CTO & Exec. Director |
| Mr. Thomas H. McLain CPA, M.B.A | Pres |
| Mr. Oliver James Sterling III | Chief Financial Officer |
| Ms. Andria Parks-Herrera | VP of Marketing |
| Ms. Jean M. Casner | Sr. VP & Chief HR Officer |
| Mr. Baljit Singh | Head of Clinical Operations |
| Dr. Michael J. Donovan M.D., Ph.D. | Chief Medical Officer |
| Mr. Salim Hamir F.C.A. | Company Sec. |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.9142 |
| Price-to-Sales TTM: | 25.8016 |
| IPO Date: | |
| Fiscal Year End: | June |
| Full Time Employees: | 102 |